PDCD1 and melanoma: Furthermore, TLSs can predict the responses to anti-PD‐1 immunotherapy and might be a target of PD‐1 blockade in several tumors including esophageal carcinoma, bladder cancer, melanoma and head and neck squamous cell carcinoma (HNSCC) (7–9, 11).